Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Operating Expenses: 2018-2021

Historic Operating Expenses for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to $26.1 million.

  • Black Diamond Therapeutics' Operating Expenses rose 12.50% to $26.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $115.3 million, marking a year-over-year increase of 65.79%. This contributed to the annual value of $126.9 million for FY2021, which is 82.37% up from last year.
  • Per Black Diamond Therapeutics' latest filing, its Operating Expenses stood at $26.1 million for Q4 2021, which was down 26.25% from $35.4 million recorded in Q3 2021.
  • Over the past 5 years, Black Diamond Therapeutics' Operating Expenses peaked at $35.4 million during Q3 2021, and registered a low of $3.0 million during Q4 2018.
  • Its 3-year average for Operating Expenses is $17.4 million, with a median of $15.0 million in 2020.
  • Data for Black Diamond Therapeutics' Operating Expenses shows a peak YoY soared of 239.59% (in 2019) over the last 5 years.
  • Black Diamond Therapeutics' Operating Expenses (Quarterly) stood at $3.0 million in 2018, then soared by 239.59% to $10.3 million in 2019, then spiked by 124.12% to $23.2 million in 2020, then rose by 12.50% to $26.1 million in 2021.
  • Its Operating Expenses was $26.1 million in Q4 2021, compared to $35.4 million in Q3 2021 and $30.7 million in Q2 2021.